Gastos do Ministério da Saúde do Brasil com Medicamentos de Alto Custo: Uma Análise Centrada no Paciente

Ruas, Cristina Mariano; Júnior, Augusto Afonso Guerra; Cherchiglia, Mariângela Leal; Andrade, Eli Iôla Gurgel; Almeida, Alessandra Maciel; Silva, Grazielle Dias da; Queiroz, Odilon Vanni de; Faleiros, Daniel Resende; Acúrcio, Francisco de Assis

doi:10.1016/j.jval.2011.05.028

Cited by 23 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another limitation is the potential duplication of patients' records within DATASUS databases; considering evidence showing that quality of data extracted from DATASUS may be compromised due to duplication or lack of consistency in the patients' registry, depending on the type of information used 18,19 . Nevertheless, with regard to the CEAF data, limitations are considerably lower, due to the need of medical prescriptions for treatment of each patient diagnosed within the SUS during the same period (monthly).…”

Section: Discussionmentioning

confidence: 99%

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

et al. 2016

View full text Add to dashboard Cite

Budget Impact Analyses require a set of essential information on health technology innovation, including expected rates of adoption. There is an absence of studies investigating trends, magnitude of budgetary effects and determinants of diffusion rates for health technology innovations worldwide during the last decades. The present study proposes a pilot assessment on main determinants influencing diffusion rates of pharmaceutical innovations within the Brazilian Unified National Health System (SUS). Data from the Brazilian Health Informatics Department (DATASUS) was gathered to establish the main determinants of diffusion rates of health technology innovations in Brazil, specifically referring to pharmaceutical innovations incorporated in the Brazilian Program for Specialized Pharmaceutical Services (CEAF) at SUS. Information was retrieved on DATASUS relating to patients who had used one of the medicines incorporated into CEAF at least three years prior to the beginning of the study (2015) for treatment of each health condition available. Thus, data from patients adopting 10 different medicines were analyzed in the study. Results from the zero-one inflated beta model showed a higher influence on diffusion rates of pharmaceutical innovations due to: number of pharmaceutical competitors for treatment of the same disease available at CEAF (negative); medicine used in combination with other medication (positive); and innovative medicine within the SUS (positive). Further research on diffusion rates of health technology innovations is required, including wider scope of diseases and medications, potential confusion factors and other variables that may influence rates of adoption in different health systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Cushing syndrome accounts for 510 cases/million/year (44) and celiac disease has a prevalence of 1% (45 Direct costs related to the management of osteoporosis: treatment It is estimated that SUS accounts for the provision of healthcare to 75.5% of the Brazilian citizens, and medications represent a sizable fraction of the public spending with health (47). The expenses of Brazil's Ministry of Health with drugs acting on bone struc ture and mineralization correspond to approximately 10.9% of the total spending with highcost medications (48). In the São Paulo public health system, in 1998, the mean annual cost for postmenopausal osteoporo sis treatment in ambulatory patients amounted to 775 dollars per patient, and outofthepocket payments by the patients corresponded to 9% of the monthly family income (49).…”

Section: Direct Costs Related To the Management Of Osteoporosis: The mentioning

confidence: 99%

The burden of osteoporosis in Brazil

Marinho

Guerra

Drummond³

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Osteoporotic fractures impose severe physical, psychosocial, and financial burden both to the patient and the society. Studies on the prevalence of osteoporosis and fragility fractures in Brazil show a wide variation, due to differences in sample size, the population studied, and methodologies. Few studies have been conducted in Brazil about the cost-effectiveness analyses of different intervention options aimed at the diagnosis and treatment of osteoporosis. Investigation and treatment strategies based on cost-effectiveness and scientific evidence are essential in the preparation of public health policies with the ultimate goal of reducing the incidence of fractures and, consequently, the direct and indirect costs associated with them. This article reviews the Brazilian burden of osteoporosis in terms of the prevalence and fractures attributable to the disease, the costs related to the investigation and management, as well as the impact of osteoporosis on the population as a whole and on affected individuals. Arq Bras Endocrinol Metab. 2014;58(5):434-43Keywords Expenses; osteoporosis; Brazil RESUMOFraturas osteoporóticas impõem graves entraves físicos, psicossociais e financeiros, tanto para o paciente quanto para a sociedade. Estudos sobre a prevalência de osteoporose e fraturas por fragilidade no Brasil mostram uma grande variação, em decorrência das diferenças no tamanho das amostras, da população estudada e da metodologia empregada. Poucos estudos têm sido realizados no Brasil sobre a análise de custo-efetividade das diferentes opções de intervenção que visam ao diagnóstico e ao tratamento da osteoporose. Estratégias de investigação e de tratamento com base na relação custo-eficácia e evidências científicas são essenciais para a elaboração de políticas de saúde pública, com o objetivo final de reduzir a incidência de fraturas e, consequentemente, os custos diretos e indiretos associados a elas. Este artigo faz uma revisão sobre o ônus da osteoporose no Brasil em termos de prevalência e fraturas atribuí-veis à doença, de custos relacionados com a investigação, tratamento da osteoporose, bem como seu impacto na população como um todo e em indivíduos afetados. Arq Bras Endocrinol Metab.

show abstract

“…For instance, a study carried out in the state of Rio de Janeiro, Brazil, found that most antimicrobial costs came from primary rather than hospital care. (5) The non-hospital environment in Brazil does not have a specific surveillance system on the rational use of drugs, including antimicrobials, which limits monitoring and controlling this drug, and favors its empirically exacerbated use. In addition, an irregular and non-directed distribution can lead to AMR and potentiate unnecessary expenses.…”

Section: Introductionmentioning

confidence: 99%

Distribuição e custo de antimicrobianos na Atenção Primária

et al. 2018

View full text Add to dashboard Cite

Objective: To analyze antimicrobial distribution and costs in primary care of a capital city in the Northeast region of Brazil. Methods: Cross-sectional, analytical study, developed in the city of Teresina, in the state of Piauí, Brazil. Data cover the period from June 2015 to July 2016. Descriptive statistics and the Kruskal-Wallis test were calculated to compare the medians of the independent data distributions. Results: A total of 1,651,516 antimicrobials were distributed in 15 different types, with amoxicillin (500mg) being the most distributed (75%) in psychosocial care centers, and in the basic health units (47%). The total cost for the period was 98,705.00 BRL. There were no statistically signifi cant differences among the costs medians in each zone of the studied municipality. Conclusion: These drugs are irregularly distributed among the units, according to the demand. The supply does not follow a specifi c protocol, and a possible increase or reduction in demand is not investigated. ResumoObjetivo: Analisar a distribuição e custos de antimicrobianos na Atenção Primária de uma capital da Região Nordeste do Brasil. Método: Estudo transversal, analítico, desenvolvido em Teresina, Piauí, Brasil. Os dados contemplam o período de junho de 2015 a julho de 2016. Calculou-se estatísticas descritivas e o Teste de Kruskal-Wallis para comparar as medianas das distribuições de dados independentes. Resultados: Foram distribuídos 1.651.516 antimicrobianos de 15 tipos diferentes dos quais a amoxicilina (500mg) foi o mais distribuído (75%) nos Centros de Atenção Psicossocial e nas Unidades Básicas de Saúde (47%). O custo total no período foi de 98.705,00 reais. Não houve diferenças estatisticamente signifi cante entre as medianas dos custos em cada zona do município estudado. Conclusão: A distribuição desses medicamentos é realizada de forma irregular entre as unidades, de acordo com a demanda. O fornecimento não segue protocolo específi co, e não se investiga um possível aumento na demanda ou redução. ResumenObjetivo: Analizar la distribución y costos de antimicrobianos en Atención Primaria de una capital del Noreste de Brasil. Método: Estudio transversal, analítico, desarrollado en Teresina, Piauí, Brasil. Datos obtenidos entre junio de 2015 y julio de 2016. Se aplicó estadística descriptiva y el Test de Kruskal-Wallis para comparar las medianas de las distribuciones de datos independientes. Resultados: Fueron distribuidos 1.651.516 antimicrobianos de 15 tipos diferentes, de los cuales la amoxicilina (500mg) fue el más entregado (75%) en Centros de Atención Psicosocial y en Unidades Básicas de Salud (47%). El costo total durante el período fue de 98.705,00 Reales. No hubo diferencia estadísticamente signifi cativa entre las medianas de costos en cada zona del municipio estudiado. Conclusión: La distribución de estos medicamentos se realiza de manera irregular entre las unidades, de acuerdo a la demanda. La provisión no cumple protocolos específi cos, y no se investiga un posible aumento o reducción de demanda.

show abstract

Gastos do Ministério da Saúde do Brasil com Medicamentos de Alto Custo: Uma Análise Centrada no Paciente

Abstract: The understanding of the expenses involved subsidizes restructuring actions and scheduling drug programs, also provides information for therapeutic groups which are priorities for analysis.

Cited by 23 publications

References 18 publications

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

Factors associated with the diffusion rate of innovations: a pilot study from the perspective of the Brazilian Unified National Health System

The burden of osteoporosis in Brazil

Distribuição e custo de antimicrobianos na Atenção Primária

Contact Info

Product

Resources

About